Author:
Tian Xin,Zhang Liuqingqing,Tang Yijia,Xiang Guiqiyang,Wang Zixuan,Zhu Ping,Yu Shuting,Jiang Fangying,Wang Shuai,Wang Jinzeng,Dai Yao,Zheng Desheng,Wang Jianbiao,Liu Han,Weng Xiangqin,Wang Shengyue,Tan Yun,Chen Zhu,Chen Saijuan,Liu Feng
Abstract
AbstractCancer differentiation therapy aims to induce maturation of neoplastic cells, yet how cell fate is determined in oncogenic cellular contexts is poorly understood. Here we integrate chromatin accessibility and transcriptome analysis at single-cell levels to investigate the mechanism driving the differentiation trajectory of the PML/RARα+acute promyeloid leukemia (APL) cell line model, NB4, under the induction of all-trans-retinoid acid (ATRA). We show that differentiating NB4 cells navigate through an intermediate cell fate decision point that leads to either terminal granulopoiesis or a transient immature-lymphocyte-like state. Functional perturbation studies indicate that ATRA signaling activates discrete PML/RARα-target enhancers to induce a positive feedforward gene regulatory circuit involving two myeloid-lineage transcription factors, SPI1 and CEBPE, which is both necessary and sufficient to activate a myelocytic gene expression program in NB4. Further, ectopic expression of SPI1 and CEBPE also promotes myelocytic differentiation in non-APL leukemia cell lines HL60 and K562. Together, these results shed light on the differentiation trajectory of therapy-induced cell decisions of APL and suggest a gene regulatory circuit that may be broadly exploited to promote terminal differentiation of leukemia.
Publisher
Cold Spring Harbor Laboratory